var data={"title":"Guanfacine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Guanfacine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6297?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=guanfacine-drug-information\" class=\"drug drug_general\">see &quot;Guanfacine: Drug information&quot;</a> and <a href=\"topic.htm?path=guanfacine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Guanfacine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178166\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Intuniv;</li>\n      <li>Tenex [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21313111\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Intuniv XR</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1017394\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Alpha<sub>2</sub>-Adrenergic Agonist</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1017415\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=guanfacine-drug-information\" class=\"drug drug_general\">see &quot;Guanfacine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Immediate release and extended release products are not interchangeable on a mg-per-mg basis due to differences in pharmacokinetic profiles. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Attention-deficit/hyperactivity disorder:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immediate release product: Limited data available (Dopheide 2009; Pliszka 2007): Children &ge;6 years and Adolescents: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&le;45 kg: Oral: Initial: 0.5 mg once daily at bedtime; may titrate every 3 to 4 days in 0.5 mg/day  increments to 0.5 mg twice daily, then 0.5 mg three times daily, then 0.5 mg four times daily; maximum daily dose: Patient weight 27 to 40.5 kg: 2 mg/<b>day</b>; 40.5 to 45 kg: 3 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&gt;45 kg: Oral: Initial: 1 mg once daily at bedtime; may titrate every 3 to 4 days in 1 mg/day increments to 1 mg twice daily, then 1 mg three times daily, then 1 mg four times daily; maximum daily dose: 4 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended release product (eg, Intuniv): Children and Adolescents 6 to 17 years: Oral: Initial: 1 mg once daily administered at the same time of day (in the morning or evening); may titrate dose  by no more than 1 mg/week increments based upon response and as tolerated to the recommended target dose range: 0.05 to 0.12 mg/kg/day or 1 to 7 mg/day. Target range based on data from monotherapy trials to balance the exposure (dose)-related potential benefits and risks (hypotension, bradycardia, and sedative effects). In clinical monotherapy trials, initial clinical response was associated with doses of 0.05 to 0.08 mg/kg once daily; increased efficacy was seen with increasing mg/kg doses; doses up to 0.12 mg/kg once daily have shown benefit when tolerated. In adjunctive therapy trials with stimulant medication, doses of 0.05 to 0.12 mg/kg/day produced optimal clinical response in the majority of patients. </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Suggested fixed target dose range for patients weighing &ge; 25 kg:</i> All doses administered once daily at the same time (either in the morning or evening) not to exceed age-based maximum daily doses.  </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">25 to 33.9 kg: 2 to 3 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">34 to 41.4 kg:  2 to 4 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">41.5 to 49.4 kg:  3 to 5 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">49.5 to 58.4 kg:  3 to 6 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">58.5 to 91 kg: 4 to 7 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;91 kg:  5 to 7 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Maximum daily doses:</i>  Doses above the following have not been evaluated.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Monotherapy: Children 6 to 12 years: 4 mg/<b>day</b>; Adolescents: 13 to 17 years: 7 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Adjunct therapy (with psychostimulants): 4 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Conversion from immediate release guanfacine to the extended release product:</i> Discontinue the immediate release product; initiate the extended release product at the doses recommended above. </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Missed doses of extended release:</i> If patient misses two or more consecutive doses, repeat titration of dose should be considered.  </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Discontinuation of extended release:</i> Taper dose by no more than 1 mg every 3 to 7 days.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Dosing adjustment for concomitant CYP3A4 inhibitors/inducers with  extended release</i>:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Strong CYP3A4 inhibitors:</i> If initiating guanfacine while taking a strong 3A4 inhibitor, decrease guanfacine dose to 50% the recommended target dose . If continuing guanfacine and adding a strong CYP3A4 inhibitor, decrease guanfacine dose by 50% the recommended target dose. If the strong CYP3A4 inhibitor is discontinued, increase  guanfacine to the recommended target dose.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Strong CYP3A4 inducers:</i> If initiating guanfacine while taking a strong CYP3A4 inducer, consider increasing dose up to double the recommended target dose. If continuing guanfacine and adding a strong CYP3A4 inducer, consider increasing guanfacine dose up to double the recommended target dose over 1 to 2 weeks. If the strong CYP3A4 inducer is discontinued, decrease guanfacine dose  to recommended target dose over 1 to 2 weeks.  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hypertension:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 years and Adolescents: Immediate release product: Oral: 1 mg usually at bedtime; may increase, if needed, at 3- to 4-week intervals; usual range: 0.5 to 2 mg/day; maximum daily dose: 2 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pervasive  developmental disorders (PDD) and ADHD:</b> Limited data available; efficacy results variable: Children and Adolescents 5 to 14 years: Immediate release product: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&lt;25 kg: Oral: Initial: 0.25 mg once daily, increase dose as tolerated every 4 days in 0.25 mg/day increments in 2 to 3 divided doses; maximum daily dose: 3 mg/<b>day</b> (Scahill 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&ge;25 kg: Oral: Initial: 0.5 mg once daily, increase dose as tolerated every 4 days in 0.5 mg/day increments in 2 to 3 divided doses; maximum daily dose: 3 mg/<b>day</b> (Handen 2008; Scahill 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dosing based on a double-blind, placebo-controlled, 6-week crossover trial conducted in children with ADHD and autism or intellectual disabilities (n=11; age: 5 to 9 years);  five of 11 patients showed improvement in hyperactivity scores; other patient assessment parameters did not show improvements (Handen, 2008). In an open-label 8-week pilot study in children with ADHD and PDD (n=25; mean age: 9 years; range: 5-14 years), patients showed improvement in parent- and teacher-rated hyperactivity subscale scores; increased irritability occurred in seven patients; the authors note that patients with PDD may be more sensitive to irritability-type adverse effects (Scahill 2006). A retrospective chart review of pediatric autism spectrum disorders (n=80; age: 3 to 18 years) reported ~24% of patients responded to mean dose of 2.6 mg/day; the authors noted patients with Asperger&rsquo;s or PDD not otherwise specified (NOS) responded more frequently than those with autistic disorder or comorbidity of mental retardation (Posey 2004). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Tic disorder; Tourette syndrome:</b>  Limited data available; greater efficacy shown in patients with ADHD comorbidity  (Murphy [AACAP 2013], Pringsheim 2012; Roessner [ESSTS 2011]; Weisman 2013): Children and Adolescents 6 to 16 years: Immediate release product: Oral: Initial: 0.5 mg once daily at bedtime for 3 days, then 0.5 mg twice daily for 4 days, then 0.5 mg 3 times daily for 7 days; further upward titration based on clinical response to maximum daily dose: 4 mg/<b>day</b> (Scahill 2001); twice daily dosing may be effective for some patients (Chappell 1995, Cummings 2002). Dosing based on a double-blind, placebo-controlled study in patients with ADHD and mild to moderate tics (n=34; mean age: 10.4 years; range: 7 to 14 years); reported final dose range: 1.5 to 3 mg/day in 3 divided doses with the most common dose reported was  2.5 mg/day (ie, 1 mg in morning, 0.5 mg at 3 pm, and 1 mg at bedtime); a statistically significant decrease (31%) in tic scores and improvement in teacher-rated ADHD scores  was reported after 8 weeks (Scahill 2001). A small open-label trial of patients with Tourette&rsquo;s syndrome and ADHD (n=10; age range: 8 to 16 years) used similar initial doses and  dose titration (0.5 mg increments every 3 to 4 days); final reported dose range: 0.75 to 3 mg/day in divided doses (2 to 3 times daily); seven of 10 patients required a final dose of 1.5 mg/day in divided doses (Chappell 1995). A short 4-week trial evaluating 24 patients (age range: 6 to 16 years) with mild chronic tic disorder showed only slight improvement in tic scores after titration (over approximately 3 weeks) to a final dose of 2 mg/day (Cummings 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Hypertension:</b> Immediate release: Oral: 1 mg once daily at bedtime, may increase if needed after 3 to 4 weeks of therapy to 2 mg daily at bedtime. <b>Note:</b> Adverse reactions increase significantly with doses above 3 mg/day.  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release: Children &ge;12 years, Adolescents, and Adults: There are no dosage adjustments provided in the manufacturer's labeling; however, the lower end of the dosing range is recommended in patients with  renal impairment; use with caution, as ~50% of the dose (40% to 75% of dose) is excreted as unchanged drug in urine. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release (Intuniv): Children &ge;6 years and Adolescents: There are no dosage adjustments provided in manufacturer's labeling (has not been studied); however, dosage adjustments may be necessary in patients with significant renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hemodialysis: Immediate release or extended release: Dialysis clearance is low (~15% of total clearance).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release: Children &ge;12 years, Adolescents, and Adults: There are no specific dosage adjustments provided in the manufacturer's labeling; however, use with caution in chronic hepatic impairment; consider dosage reduction. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release (Intuniv): Children &ge;6 years and Adolescents: There are no dosage adjustments provided in manufacturer's labeling (has not been studied); however, dosage adjustments may be necessary in patients with significant hepatic impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178152\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tenex: 1 mg [DSC] [contains fd&amp;c red #40 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tenex: 2 mg [DSC] [contains fd&amp;c yellow #10 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 mg, 2 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release 24 Hour, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Intuniv: 1 mg, 2 mg, 3 mg, 4 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 mg, 2 mg, 3 mg, 4 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178139\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10105744\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immediate release: Take at bedtime to minimize somnolence </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extended release: Take at the same time each day (either morning or evening); swallow tablet whole with water, milk, or other liquid; do not crush, break, or chew; do not administer with high-fat meal </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9612502\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immediate release: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extended release: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted between 15&deg;C and 30&deg;C (59&deg;F and 86&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1017395\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immediate release: Management of hypertension alone or in combination with other hypertensive agents, especially thiazide-type diuretics (FDA approved ages &ge;12 years and adults); has also been used in attention-deficit/hyperactivity disorder (ADHD), including ADHD with tic disorder (or Tourette's syndrome) and ADHD with autism or pervasive developmental disorders (PDD) comorbidities</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extended release: Treatment of ADHD as monotherapy or adjunctive therapy with stimulant medication (FDA approved in ages 6 to 17 years)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178195\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">GuanFACINE may be confused with guaiFENesin, guanabenz, guanidine</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Intuniv may be confused with Invega</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Tenex may be confused with Entex, Xanax</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Guanfacine is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) due to high risk of CNS adverse effects and risk of bradycardia and orthostatic hypotension associated with central alpha blockers; not recommended as routine treatment for hypertension (Beers Criteria [AGS 2015]).</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Pharmacy Quality Alliance (PQA): Guanfacine is identified as a high-risk medication in patients 65 years and older on the PQA&rsquo;s, Use of High-Risk Medications in the Elderly (HRM) performance measure, a safety measure used by the Centers for Medicare and Medicaid Services (CMS) for Medicare plans.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Tenex [U.S.] may be confused with Kinex brand name for biperiden [Mexico]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178194\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Atrioventricular block, bradycardia, chest pain, hypertension, hypotension (dose-related; includes orthostatic), sinus arrhythmia, syncope</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Agitation, anxiety, depression, dizziness (dose-related), drowsiness (dose-related), emotional lability (children and adolescents 6 to 17 years), fatigue, headache, insomnia, irritability, lethargy, nightmares, seizure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Pallor, pruritus, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Weight gain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain (dose-related), constipation (dose-related), decreased appetite, diarrhea, dyspepsia, nausea, stomach pain, vomiting, xerostomia (dose-related)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Impotence, urinary frequency, urinary incontinence</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased serum ALT</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Asthma</p>\n    <p style=\"text-indent:-4em;margin-left:4em;\">Miscellaneous: Fever (Biederman 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Alopecia, amnesia, cardiac fibrillation, cerebrovascular accident, dermatitis, dysphagia, exacerbation of cardiac disease (sinus node dysfunction, atrioventricular block), exfoliative dermatitis, hallucination, hypertensive encephalopathy (with abrupt discontinuation), hypokinesia, iritis, mania (immediate release; children), myocardial infarction, nocturia, palpitations, paresis, Raynaud phenomenon, rebound hypertension, renal failure, tachycardia, visual disturbance</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178156\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to guanfacine or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178143\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular effects: May cause atrioventricular (AV) block, bradycardia, hypotension, orthostasis, sinus node dysfunction, and syncope; these effects are dose-dependent, more pronounced during the first month of therapy, or may worsen especially when used with other sympatholytic drugs. Monitor vital signs frequently in patients with cardiac conduction abnormalities or those concomitantly treated with other sympatholytic drugs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS effects: May cause sedation and drowsiness which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery, driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatological effects: Skin rash with exfoliation and pruritus have been reported; discontinue guanfacine and monitor patients who develop a rash.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with severe coronary insufficiency, recent MI, or a history of bradycardia, cardiovascular disease, heart block, hypotension, or syncope. Cautious use is also recommended in patients with conditions that predispose them to syncope (eg, orthostasis, dehydration).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cerebrovascular disease: Use with caution in patients with cerebrovascular disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with chronic hepatic impairment. Dosage adjustment may be necessary in severe impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with chronic renal impairment. Dosage adjustment may be necessary in severe impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Product interchangeability: Formulations of guanfacine (immediate release versus extended release) are not interchangeable on a mg to mg basis because bioavailability, C<sub>max</sub>, and T<sub>max</sub> vary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Discontinuation of therapy: Increased heart rate and rebound hypertension have been reported with abrupt discontinuation; hypertensive encephalopathy has also been reported. Increased risk of rebound hypertension may occur in children with GI illnesses and vomiting. Concomitant stimulant use may increase blood pressure if guanfacine is abruptly stopped. To minimize these effects, taper the dose in decrements of &le;1 mg every 3 to 7 days and monitor blood pressure and pulse following dosage reduction/discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; ADHD treatment: Appropriate use: Recommended to be used as part of a comprehensive treatment program for attention-deficit disorders; safety and efficacy of long-term use for the treatment of ADHD (&gt;2 years) have not been established (Sallee 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25881856\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">The American Heart Association recommends that all children diagnosed with ADHD who may be candidates for medication, such as guanfacine, should have a thorough cardiovascular assessment prior to initiation of therapy. These recommendations are based upon reports of serious cardiovascular adverse events (including sudden death) in patients (both children and adults) taking usual doses of stimulant medications. Most of these patients were found to have underlying structural heart disease (eg, hypertrophic obstructive cardiomyopathy). This assessment should include a combination of thorough medical history, family history, and physical examination. An ECG is not mandatory but should be considered. <b>Note:</b> In older clinical data, ECG abnormalities and four cases of sudden cardiac death were reported in children receiving clonidine (a less selective alpha<sub>2</sub>-agonist) with methylphenidate; reduce dose of methylphenidate by 40% when used concurrently with clonidine; consider ECG monitoring. However, more recent (published after 2001) multicenter trials have not reported serious cardiovascular outcomes or events in medically screened children and adolescents receiving concomitant clonidine and psychostimulant therapy; the most frequent reported adverse effects with combination therapy were drowsiness, dizziness, and somnolence (Wilens, 2012). A double-blind, placebo-controlled trial of 461 pediatric patients (age: 6 to 17 years) examining the effect of the addition of extended release guanfacine to current psychostimulant therapy did not report any cardiovascular adverse events; in this trial, the most common (&gt;10% incidence) treatment emergent adverse effects were headache, somnolence, fatigue, and dizziness (Wilens, 2012). Further studies are needed to examine the long-term safety and efficacy of guanfacine in combination with psychostimulants.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">When discontinuing guanfacine ADHD therapy, an increase in blood pressure has been observed in children and adolescents (6 to 17 years); increases in mean systolic and diastolic blood pressure, of ~3 mm Hg and 1 mm Hg respectively above baseline were reported; monitor vital signs.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9837647\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178147\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=15555&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): May enhance the CNS depressant effect of GuanFACINE.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: Alpha2-Agonists may enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the Alpha2-Agonist is abruptly withdrawn.  Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.<b> Exceptions: </b>Levobunolol; Metipranolol.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bretylium: May enhance the bradycardic effect of Bradycardia-Causing Agents. Bretylium may also enhance atrioventricular (AV) blockade in patients receiving AV blocking agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine patches (Butrans brand) at 5 mcg/hr in adults when used with other CNS depressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib.  Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of GuanFACINE. Management: Increase the guanfacine dose by up to double when initiating concomitant therapy with moderate CYP3A4 inducers. Increase guanfacine dose gradually over 1-2 weeks if moderate CYP3A4 inducer therapy is just beginning.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May decrease the serum concentration of GuanFACINE. Management: Increase the guanfacine dose by up to double when initiating concomitant therapy with strong CYP3A4 inducers. Increase guanfacine dose gradually over 1-2 weeks if strong CYP3A4 inducer therapy is just beginning.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of GuanFACINE. Management: Reduce the guanfacine dose by 50% when initiating this combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of GuanFACINE. Management: Reduce the guanfacine dose by 50% when initiating this combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxylamine: May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is  not recommended.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CNS Depressants may enhance the CNS depressant effect of HYDROcodone.  Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iobenguane I 123: Alpha2-Agonists may diminish the therapeutic effect of Iobenguane I 123. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ivabradine: Bradycardia-Causing Agents may enhance the bradycardic effect of Ivabradine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirtazapine: May diminish the antihypertensive effect of Alpha2-Agonists. Management: Consider avoiding concurrent use.  If the combination cannot be avoided, monitor for decreased effects of alpha2-agonists if mirtazapine is initiated/dose increased, or increased effects if mirtazapine is discontinued/dose decreased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: CNS Depressants may enhance the CNS depressant effect of Opioid Analgesics.  Management: Avoid concomitant use of opioid analgesics and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ruxolitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents. Management: Ruxolitinib Canadian product labeling recommends avoiding use with bradycardia-causing agents to the extent possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin/Norepinephrine Reuptake Inhibitors: May diminish the antihypertensive effect of Alpha2-Agonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of GuanFACINE. Management: Consider increasing the guanfacine dose by 2-fold when adding St Johns Wort.  Titrate the guanfacine dose up to a max of 8 mg/day when starting guanfacine in a patient who is taking St Johns Wort.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Terlipressin: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants: May diminish the antihypertensive effect of Alpha2-Agonists.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Valproate Products: GuanFACINE may increase the serum concentration of Valproate Products. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Yohimbine: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45501431\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Grapefruit juice/products: Because of potential inhibition of CYP3A4-mediated metabolism of guanfacine, the Canadian labeling recommends avoiding use of these products during therapy with guanfacine.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178148\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9612487\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies except in doses that also caused maternal toxicity. Information related to guanfacine use during pregnancy is limited (Philipp 1980). Untreated chronic maternal hypertension is associated with adverse events in the fetus, infant, and mother. If treatment for hypertension during pregnancy is needed, other agents are preferred (ACOG 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10268673\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Heart rate, blood pressure, consider ECG monitoring in patients with history of heart disease or concurrent use of medications affecting cardiac conduction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">ADHD: Evaluate patients for cardiac disease prior to initiation of therapy for ADHD with thorough medical history, family history, and physical exam; consider ECG; perform ECG and echocardiogram if findings suggest cardiac disease; promptly conduct cardiac evaluation in patients who develop chest pain, unexplained syncope, or any other symptom of cardiac disease during treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178142\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Guanfacine is a selective alpha<sub>2A</sub>-adrenoreceptor agonist that reduces sympathetic nerve impulses, resulting in reduced sympathetic outflow and a subsequent decrease in vasomotor tone and heart rate.  In addition, guanfacine preferentially binds postsynaptic alpha<sub>2A</sub>-adrenoreceptors in the prefrontal cortex and has been theorized to improve delay-related firing of prefrontal cortex neurons. As a result, underlying working memory and behavioral inhibition are affected; thereby improving symptoms associated with ADHD.  Guanfacine is not a CNS stimulant. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178155\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">\n      <b>Note: </b>When dosed at same mg dose, the extended-release product has a lower peak serum concentration (60% lower) and AUC (43% lower) compared with the immediate-release formulation. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Readily absorbed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Antihypertensive effect: 24 hours following single dose </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Immediate release: 6.3 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Extended release: V<sub>d</sub> (apparent): Children &ge;6 years: 23.7 L/kg; Adolescent: 19.9 L/kg (Boellner 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: ~70%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic via CYP3A4. Approximately 50% of clearance is hepatic.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Immediate release: ~80%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Extended release (relative to immediate release): 58%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Immediate release: ~17 hours (range: 10 to 30 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Extended release: Children &ge;6 years: 14.4 hours; Adolescents: 18 hours (Boellner 2007); Adults: 16 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Immediate release: 2.6 hours (range: 1 to 4 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Extended release: Children &ge;6 years and Adolescents: 5 hours (Boellner 2007); Adults: 4 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (~50%  [40% to 75% of dose] as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15597846\" class=\"nested sp-pop-child-nested drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;\">Exposure to guanfacine was higher in children (6 to 12 years of age) compared with adolescents (13 to 17 years of age).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1017420\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">Guanfacine is a more selective alpha<sub>2</sub>-agonist than clonidine; therefore, has less sedation and dizziness associated with use than clonidine; withdrawal effects less commonly occur due to its longer half-life.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Medications used to treat ADHD should be part of a total treatment program that may include other components, such as psychological, educational, and social measures. Long-term usefulness of guanfacine for the treatment of ADHD should be periodically re-evaluated in patients receiving the drug for extended periods of time.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178159\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (GuanFACINE HCl ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (100): $1,049.11</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (100): $1,049.11</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3 mg (100): $1,049.11</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg (100): $1,049.11</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Intuniv Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (100): $1,165.68</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (100): $1,165.68</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3 mg (100): $1,165.68</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg (100): $1,165.68</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (GuanFACINE HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (100): $87.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (100): $117.60</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178160\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Dipresan (HR);</li>\n      <li>Estulic (BE, BF, BJ, CH, CI, CZ, DE, ET, FR, GH, GM, GN, HN, HU, ID, JP, KE, LR, MA, ML, MR, MU, MW, NE, NG, NL, PH, RU, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW);</li>\n      <li>Estulik (UA);</li>\n      <li>Hipertensal (AR);</li>\n      <li>Intuniv (IE, JP)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics/American Heart Association Clarification of Statement on Cardiovascular Evaluation and Monitoring of Children and Adolescents With Heart Disease Receiving Medications for ADHD; available at: http://americanheart.mediaroom.com/index.php?s=43&amp;item=422.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG), &quot;ACOG Practice Bulletin No. 125: Chronic Hypertension in Pregnancy,&quot; <i>Obstet Gynecol</i>, 2012, 119(2 Pt 1):396-407.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/22270315/pubmed\" target=\"_blank\" id=\"22270315\">22270315</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Biederman J, Melmed RD, Patel A, et al, &ldquo;A Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine Extended Release in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder,&rdquo; <i>Pediatrics</i>, 2008, 121(1):e73-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/18166547/pubmed\" target=\"_blank\" id=\"18166547\">18166547</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Biederman J, Melmed RD, Patel A, et al, &quot;Long-Term, Open-Label Extension Study of Guanfacine Extended Release in Children and Adolescents With ADHD,&quot; <i>CNS Spectr</i>, 2008, 13(12):1047-55.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/19179940/pubmed\" target=\"_blank\" id=\"19179940\">19179940</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Boellner SW, Pennick M, Fiske K, et al, &quot;Pharmacokinetics of a Guanfacine Extended-Release Formulation in Children and Adolescents With Attention-Deficit-Hyperactivity Disorder,&quot; <i>Pharmacotherapy</i>, 2007, 27(9):1253-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/17723079/pubmed\" target=\"_blank\" id=\"17723079\">17723079</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chappell PB, Riddle MA, Scahill L, et al, &quot;Guanfacine Treatment of Comorbid Attention-Deficit Hyperactivity Disorder and Tourette's Syndrome: Preliminary Clinical Experience,&quot; <i>J Am Acad Child Adolesc Psychiatry</i>, 1995, 34(9):1140-6. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo; <i>JAMA</i>, 2003, 289(19):2560-71. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cummings DD, Singer HS, Krieger M, et al, &quot; Neuropsychiatric Effects of Guanfacine in Children With  Mild Tourette Syndrome: A Pilot Study,&quot; <i>Clin Neuropharmacol</i>, 2002,  25(6):325-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/12469007/pubmed\" target=\"_blank\" id=\"12469007\">12469007</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dopheide JA and Pliszka SR, &quot;Attention-Deficit-Hyperactivity Disorder: An Update,&quot; <i>Pharmacotherapy</i>, 2009, 29(6):656-79.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/19476419/pubmed\" target=\"_blank\" id=\"19476419\">19476419</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Handen BL, Sahl R, and Hardan AY, &quot;Guanfacine in Children With Autism and/or Intellectual Disabilities,&quot; <i>J Dev Behav Pediatr</i>, 2008, 29(4):303-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/18552703/pubmed\" target=\"_blank\" id=\"18552703\">18552703</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Intuniv (guanfacine) [prescribing information]. Wayne, PA: Shire US Inc; February 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Murphy TK, Lewin AB, Storch EA, et al. Practice parameter for the assessment and treatment of children and adolescents with tic disorders. <i>J Am Acad Child Adolesc Psychiatry</i>. 2013;52(12):1341-1359.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/24290467 /pubmed\" target=\"_blank\" id=\"24290467 \">24290467 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Philipp E, &quot;Guanfacine in the Treatment of Hypertension Due to Pre-eclamptic Toxaemia in Thirty Women,&quot; <i>Br J Clin Pharmacol</i>, 1980, 10(Suppl 1):137-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/6994768/pubmed\" target=\"_blank\" id=\"6994768\">6994768</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pliszka S and AACAP Work Group on Quality Issues, &quot;Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder,&quot; <i>Am Acad Child Adolesc Psychiatry</i>, 2007, 46(7):894-921. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/17581453/pubmed\" target=\"_blank\" id=\"17581453\">17581453</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Posey DJ, Puntney JI, Sasher TM, et al, &quot;Guanfacine Treatment of Hyperactivity and Inattention in Pervasive Developmental Disorders: A Retrospective Analysis of 80 Cases,&quot; <i>J Child Adolesc Psychopharmacol</i>, 2004, 14(2):233-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/15319020/pubmed\" target=\"_blank\" id=\"15319020\">15319020</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pringsheim T, Doja A, Gorman D, et al. Canadian guidelines for the evidence-based treatment of tic disorders: pharmacotherapy. <i>Can J Psychiatry</i>. 2012;57(3):133-143.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/22397999 /pubmed\" target=\"_blank\" id=\"22397999 \">22397999 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roessner V, Plessen KJ, Rothenberger A, et al. European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment. <i>Eur Child Adolesc Psychiatry</i>. 2011;20(4):173-196.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/21445724 /pubmed\" target=\"_blank\" id=\"21445724 \">21445724 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sallee FR, Lyne A, Wigal T, et al, &ldquo;Long-Term Safety and Efficacy of Guanfacine Extended Release in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder,&rdquo; <i>J Child Adolesc Psychopharmacol</i>, 2009, 19(3):215-26.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/19519256/pubmed\" target=\"_blank\" id=\"19519256\">19519256</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sallee FR, McGough J, Wigal T, et al, &ldquo;Guanfacine Extended Release in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: A Placebo-Controlled Trial,&rdquo; <i>J Am Acad Child Adolesc Psychiatry</i>, 2009, 48(2):155-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/19106767/pubmed\" target=\"_blank\" id=\"19106767\">19106767</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Scahill L, Aman MG, McDougle CJ, et al, &quot;A Prospective Open Trial of Guanfacine in Children With Pervasive Developmental Disorders,&quot; <i>J Child Adolesc Psychopharmacol</i>, 2006, 16(5):589-98.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/17069547/pubmed\" target=\"_blank\" id=\"17069547\">17069547</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Scahill L, Chappell PB, Kim YS, et al, &quot;A Placebo-Controlled Study of Guanfacine in the Treatment of Children With Tic Disorders and Attention Deficit Hyperactivity Disorder,&quot;  <i>Am J Psychiatry</i>, 2001, 158(7):1067-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/11431228/pubmed\" target=\"_blank\" id=\"11431228\">11431228</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Scahill L, &quot;Alpha-2 Adrenergic Agonists in Attention Deficit Hyperactivity Disorder,&quot; <i>J Pediatr</i>, 2009, 154:S32-7.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Spencer TJ, Greenbaum M, Ginsberg LD, et al, &quot;Safety and Effectiveness of Coadministration of Guanfacine Extended Release and Psychostimulants in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder,&quot; <i>J Child Adolesc Psychopharmacol</i>, 2009, 19(5):501-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/19877974/pubmed\" target=\"_blank\" id=\"19877974\">19877974</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vetter VL, Elia J, Erickson C, et al, &quot;Cardiovascular Monitoring of Children and Adolescents With Heart Disease Receiving Medications for Attention Deficit/Hyperactivity Disorder [Corrected]: A Scientific Statement From the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing,&quot; <i>Circulation</i>, 2008, 117(18):2407-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/18427125/pubmed\" target=\"_blank\" id=\"18427125\">18427125</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wilens TE, Bukstein O, Brams M, et al, &quot;A Controlled Trial of Extended-Release Guanfacine and Psychostimulants for Attention-Deficit/Hyperactivity Disorder,&quot; <i>J Am Acad Child Adolesc Psychiatry</i>, 2012, 51(1):74-85.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/22176941/pubmed\" target=\"_blank\" id=\"22176941\">22176941</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weisman H, Qureshi IA, Leckman JF, Scahill L, Bloch MH. Systematic review: pharmacological treatment of tic disorders--efficacy of antipsychotic and alpha-2 adrenergic agonist agents. <i>Neurosci Biobehav Rev</i>. 2013;37(6):1162-1171.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 15555 Version 199.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F178166\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F21313111\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1017394\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1017415\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F178152\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F178139\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F10105744\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F9612502\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1017395\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F178195\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F178194\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F178156\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F178143\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25881856\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F9837647\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F178147\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F45501431\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F178148\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F9612487\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F10268673\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F178142\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F178155\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics: Additional Pediatric Considerations\" href=\"#F15597846\" class=\"outlineLink\">Pharmacodynamics/Kinetics: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F1017420\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F178159\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F178160\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/15555|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=guanfacine-drug-information\" class=\"drug drug_general\">Guanfacine: Drug information</a></li><li><a href=\"topic.htm?path=guanfacine-patient-drug-information\" class=\"drug drug_patient\">Guanfacine: Patient drug information</a></li></ul></div></div>","javascript":null}